Head-to-head evidence
Ansofaxine hydrochloride vs Liafensine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: Serotonin/norepinephrine/dopamine transporter · full Major Depressive Disorder pipeline
Ansofaxine hydrochloride
Developed by Luye Pharma Group
NCT04853407 · Phase 3 · completed
This was a randomized, quadruple-blinded, placebo-controlled trial with 558 patients and a validated depression-severity scale as the primary endpoint. Both ansofaxine doses significantly outperformed placebo (MADRS reductions of 20.0 and 19.9 points versus 14.6 with placebo, p<0.0001).
Next expected readout: February 2027 · NCT06426485 (registry estimate)
Liafensine
Developed by Bristol-Myers Squibb and partners
NCT05113771 · Phase 2 · completed
The study randomized 197 participants to two liafensine doses or placebo, with participants and investigators blinded to treatment. Its primary clinical endpoint, change in MADRS score at Day 42 in DGM4-positive patients, favored combined liafensine over placebo with statistical significance, supporting a strong evidence grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ansofaxine hydrochloride's landscape · Liafensine's landscape